No Data
No Data
[Brokerage Focus] First Shanghai recommends buying CSPC Pharma (01093) and expects its new products to be approved successively, with the pharmaceutical sector poised to resume high growth.
Jingu Financial News | First Shanghai issued a research report, cspc pharma (01093) achieved a revenue of 16.28 billion yuan in the first half of 2024 (+1.3% year-on-year, the same below), gross profit of 11.65 billion yuan (+3.7%), gross margin of 71.6% (+1.7pts). Based on the financial statements, the net profit attributable to shareholders was 2.02 billion yuan (+1.8%), with a net margin of 18.5% (+0.1pts). Looking at the sectors, the traditional Chinese medicine sector generated revenue of 13.55 billion yuan (+4.8%), with a significant sequential decline in Q2 revenue; although the price of vitamin C raw materials is slowly recovering, demand is decreasing.
First Shanghai (00227.HK) received an increase of 1.576 million shares by executive director and chairman Lou Yuanyi.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on September 27, 2024, First Shanghai (00227.HK) saw Director and Chairman Law Yuen Yat adding 1.576 million shares at an average price of HK$0.15 per share, with a total investment of approximately HK$0.2364 million. Following the shareholding increase, Law Yuen Yat's latest shareholding is 1,173,051,847 shares, and the shareholding ratio has risen from 53.48% to 53.55%.
First Shanghai Investments Limited's (HKG:227) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 400% Last Week
First Shanghai: Buy rating for Yuexue Education (03978) with a target price of 5.6 Hong Kong dollars.
first shanghai expects outstanding education (03978) income forecast to reach 1.091/1.952/2.449 billion yuan for the years 2024-2026.
Gift Holdings Launches First Shanghai Store
FIRST SHANGHAI: INTERIM REPORT 2024
No Data
No Data